Innate Pharma SA (IPHYF)
2.65
0.00 (0.00%)
USD |
OTCM |
Apr 26, 16:00
Innate Pharma Debt to Equity Ratio: 0.7525 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.7525 |
| June 30, 2023 | 0.7027 |
| December 31, 2022 | 0.7577 |
| June 30, 2022 | 0.3728 |
| December 31, 2021 | 0.3857 |
| June 30, 2021 | 0.1236 |
| December 31, 2020 | 0.0997 |
| June 30, 2020 | 0.0906 |
| December 31, 2019 | 0.0717 |
| June 30, 2019 | 0.012 |
| December 31, 2018 | 0.0145 |
| June 30, 2018 | 0.0112 |
| December 31, 2017 | 0.0331 |
| June 30, 2017 | 0.0174 |
| December 31, 2016 | 0.0165 |
| Date | Value |
|---|---|
| June 30, 2016 | 0.0217 |
| December 31, 2015 | 0.0208 |
| June 30, 2015 | 0.0217 |
| December 31, 2014 | 0.0201 |
| June 30, 2014 | 0.0176 |
| December 31, 2013 | 0.0405 |
| June 30, 2013 | 0.029 |
| December 31, 2012 | 0.0321 |
| June 30, 2012 | 0.00 |
| December 31, 2011 | 0.0909 |
| June 30, 2011 | 0.00 |
| December 31, 2010 | 0.1987 |
| June 30, 2010 | 0.00 |
| December 31, 2009 | 0.1603 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.012
Minimum
Jun 2019
0.7577
Maximum
Dec 2022
0.3369
Average
0.2482
Median
Debt to Equity Ratio Benchmarks
| DBV Technologies SA | -- |
| Cellectis SA | 0.4195 |
| PHAXIAM Therapeutics SA (DELISTED) | -- |
| Genfit SA | 0.9462 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 203.61M |
| Total Liabilities (Quarterly) | 146.24M |
| Shareholders Equity (Quarterly) | 57.37M |
| Current Ratio | 3.734 |
| Net Debt Paydown Yield | 0.31% |